Avacta Group (OTCMKTS:AVCTF – Get Rating) is one of 354 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare Avacta Group to related companies based on the strength of its profitability, earnings, analyst recommendations, risk, dividends, valuation and institutional ownership.
Profitability
This table compares Avacta Group and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Avacta Group | N/A | N/A | N/A |
| Avacta Group Competitors | -277.54% | -64.91% | -14.33% |
Institutional & Insider Ownership
26.6% of shares of all “Biotechnology” companies are held by institutional investors. 26.0% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Valuation & Earnings
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Avacta Group | N/A | N/A | -3,750.00 |
| Avacta Group Competitors | $145.44 million | -$6.30 million | 24.94 |
Avacta Group’s peers have higher revenue, but lower earnings than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Analyst Ratings
This is a summary of recent ratings for Avacta Group and its peers, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Avacta Group | 0 | 0 | 0 | 0 | N/A |
| Avacta Group Competitors | 281 | 1544 | 3747 | 33 | 2.63 |
As a group, “Biotechnology” companies have a potential upside of 79.12%. Given Avacta Group’s peers higher probable upside, analysts clearly believe Avacta Group has less favorable growth aspects than its peers.
Summary
Avacta Group peers beat Avacta Group on 5 of the 8 factors compared.
About Avacta Group
Avacta Group Plc develops cancer therapies and diagnostics in the United Kingdom, France, North America, South Korea, and rest of Asia and Europe. The company operates through Diagnostics and Therapeutics segments. It develops products based on its proprietary Affimer and pre|CISION technology platforms. The company develops AVA6000, FAPa-activated doxorubicin that is in Phase I clinical trial for treating locally advanced or metastatic-selected solid tumors; AVA3996, a tumor-targeted proteasome inhibitor based on bortezomib; AVA-028-PD-L1 Affimer/ImmunoCytokines; AVA-021 – PD-L1 Affimer/LAG-3 Affimer; and TMAC platform that utilizes the proprietary pre|CISION substrate to provide for the selective release of a drug moiety by FAPa. The company has a collaboration agreement with LG Chem for developing and commercializing LR19128 PD-L1 XT; and collaboration and license agreement with Avacta and Daewoong Pharmaceutical Co. Ltd. for developing AFX-001 for solid organ transplant and graft vs host Disease, and AFX-002 for multiple sclerosis. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.
Receive News & Ratings for Avacta Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avacta Group and related companies with MarketBeat.com's FREE daily email newsletter.
